584 related articles for article (PubMed ID: 26549339)
1. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
Asero R
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
[TBL] [Abstract][Full Text] [Related]
2. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
3. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
4. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
[TBL] [Abstract][Full Text] [Related]
5. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
6. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
9. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
10. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen.
Martínez-Cañavate Burgos A; Torres-Borrego J; Molina Terán AB; Corzo JL; García BE; Rodríguez Pacheco R; Moreno Aguilar C; Dávila I
Pediatr Allergy Immunol; 2018 Jun; 29(4):369-374. PubMed ID: 29369414
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous SCIT with 2 separate allergen extracts demonstrates comparable safety compared to SCIT with a single allergen extract.
Röder A; Darrelmann N; Klingenberg W; Krüll M; Suttorp N; Noga O
J Investig Allergol Clin Immunol; 2009; 19(6):512-3. PubMed ID: 20128433
[No Abstract] [Full Text] [Related]
13. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
14. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
[TBL] [Abstract][Full Text] [Related]
15. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
16. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
17. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
18. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass.
Bozek A; Kolodziejczyk K; Krajewska-Wojtys A; Jarzab J
Ann Allergy Asthma Immunol; 2016 Feb; 116(2):156-61. PubMed ID: 26815709
[TBL] [Abstract][Full Text] [Related]
19. Systemic and large local reactions during subcutaneous grass pollen immunotherapy in children.
Gur Cetinkaya P; Kahveci M; Esenboğa S; Karaatmaca B; Soyer O; Sekerel BE; Tuncer A; Sahiner UM
Pediatr Allergy Immunol; 2020 Aug; 31(6):643-650. PubMed ID: 32320504
[TBL] [Abstract][Full Text] [Related]
20. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
